Carl Morris, Ph.D, is a Senior Director for Pfizer’s Rare Disease Research Unit, leading efforts in protein therapeutics and muscle biology programs. Currently, Dr. Morris is directing several programs, including one currently in Phase I, and also leads a research group focused on developing protein therapeutic approaches for neuromuscular and other rare diseases. Prior to joining Pfizer in 2007, Dr. Morris was an Assistant Professor at Boston University School of Medicine following his Postdoctoral fellowship at the University of Pennsylvania. During his time in industry, Dr. Morris has directed drug development efforts as a project leader for small molecule and biotherapeutic research programs, as well as leading research groups responsible for supporting and advancing both preclinical and clinical programs in development. Dr. Morris holds a B.A. in Biology from Franklin Pierce College (NH) and a PhD in Physiology from UCLA.